RENALYTIX PLC - AMERICAN DEPOSITARY SHARES

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

24 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology

17 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix Announces Change to Board of Directors

20 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

08 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

30 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30

23 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

10 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix to Present at 42nd Annual William Blair Growth Stock Conference

08 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

06 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®

02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Renalytix plc successful completion of $30.0 million financing package

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix plc Issue of shares

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix announces a $30.0 million financing package

31 Mar 2022 07:05:00 By Nasdaq GlobeNewswire

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

31 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

30 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31

25 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform

09 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care

24 Feb 2022 07:00:01 By Nasdaq GlobeNewswire